Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGIOS PHARMACEUTICALS, INC. Director's Dealing 2025

Jun 23, 2025

31580_dirs_2025-06-23_55492f45-dc06-45a9-95e1-7ca6106dfa14.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2025-06-18

Reporting Person: CAPELLO JEFFREY D (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-06-20 Common stock M 2120 Acquired 6073 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-06-18 Restricted stock units $ A 2861 Acquired Common stock (2861) Direct
2025-06-18 Stock options (right to buy) $35.50 A 15768 Acquired 2035-06-18 Common stock (15768) Direct
2025-06-20 Restricted stock units $ M 2120 Disposed Common stock (2120) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3: These options were granted on June 18, 2025. The shares underlying this option vest as to 100% of the underlying shares on June 18, 2026.

F4: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.